Anti-tumor effect of GTN in combination with standard chemotherapeutic agent & anti-PD-1
The aims of this axis are:
- To study the anti-tumor activity of the combination of GTN with standard chemotherapies (FOLFOX, Doxorubicin, Gemcitabine ...) combined or not with anti-PD-1 immunotherapy in the treatment of solid cancers (colon, breast, lung ...) at an advanced stage,
- To determine the role of immune cells in the innate and adaptive anti-tumor response induced by these combinations,
- To determine the potential molecular targets of these combinations at the level of the cancer cell,
- To establish a clinical trial in patients with cancer.